Brand-name Drugs

AstraZeneca Signs U.S. Drug-Pricing Deal, Pledges MFN Medicaid Rates and TrumpRx Participation

The agreement showcases a tariff‑for‑concessions approach that ties Medicaid parity pricing to future TrumpRx participation.